Page last updated: 2024-12-06

marbofloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Marbofloxacin is a synthetic fluoroquinolone antibacterial agent that is effective against a wide range of gram-positive and gram-negative bacteria. It is used in veterinary medicine to treat bacterial infections in various animal species, including dogs, cats, horses, cattle, and pigs. The synthesis of marbofloxacin involves a multi-step process starting from commercially available starting materials. Marbofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and cell division. This inhibition leads to the disruption of bacterial DNA synthesis and ultimately cell death. The importance of marbofloxacin lies in its broad-spectrum activity, good bioavailability, and long duration of action. It is also effective against many bacteria that have developed resistance to other antibiotics. Marbofloxacin is studied extensively to investigate its efficacy, safety, and pharmacokinetic properties in different animal species. Researchers are also exploring potential applications of marbofloxacin in human medicine, particularly for the treatment of multidrug-resistant bacterial infections.'

Cross-References

ID SourceID
PubMed CID60651
CHEMBL ID478120
CHEBI ID94723
SCHEMBL ID134860
MeSH IDM0214511

Synonyms (84)

Synonym
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid
marbofloxacin ,
marbofloxacinum [inn-latin]
marbofloxacine [inn-french]
marbofloxacin [inn]
marbofloxacino [inn-spanish]
7h-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
OPREA1_079403
NCGC00166310-01
marbofloxacine
marbofloxacinum
marbofloxacino
115550-35-1
marbofloxacin (usp/inn)
D08156
ro 09-1168
marbocyl
CHEMBL478120
9-fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2h-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid
M2240
dtxsid4046600 ,
dtxcid2026600
cas-115550-35-1
tox21_112406
unii-8x09wu898t
8x09wu898t ,
ccris 8212
marbofloxacin [inn:ban]
zeniquin
BCP9000896
FT-0628168
NCGC00166310-03
marbofloxacin [mart.]
marbofloxacin [green book]
marbofloxacin [mi]
S1464
AKOS015853291
HY-B0126
CS-1892
SCHEMBL134860
NCGC00166310-02
tox21_112406_1
Q-201338
7h-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid
AC-24289
AB01566820_01
mfcd00864820
CCG-229989
EX-A015
GS-3323
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13}]trideca-5,7,9(13),11-tetraene-11-carboxylic acid
SR-01000772975-2
sr-01000772975
marbofloxacin, vetranal(tm), analytical standard
CHEBI:94723
marbofloxacin for peak identification, european pharmacopoeia (ep) reference standard
marbofloxacin, european pharmacopoeia (ep) reference standard
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid; aurizon; marbocyl; marbofloxacin; zeniquin
rkl10084
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2- diazatricyclo[7.3.1.0^5,13^]trideca-5,7,9(13),11-tetraene-11-carboxylic acid
9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)- 7-oxo-7h-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl -1-piperazinyl)-7-oxo-7h-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid
DB11426
Q909359
H10130
7-fluoro-2-methyl-6-(4-methylpiperazin-4-ium-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylate
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid
marbofloxacin for peak identification
BM164656
7h-1,3,4-oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
marbofloxacin (mart.)
marbofloxacino (inn-spanish)
marbofloxacin chewable tablets
marboquin
fluroflox
marbofloxacine (inn-french)
delaquin
marbofloxacinum (inn-latin)
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyridol(3,2,1-ij)(4,2,1)benzoxadiazin-6 carboxylic acid
marboflooxacin

Research Excerpts

Overview

Marbofloxacin (MAR) is an antimicrobial belonging to the fluoroquinolone class. It is marketed in the form of tablets. There is no microbiological monograph in official compendia to evaluate the potency of the final product.

ExcerptReferenceRelevance
"Marbofloxacin (MAR) is an antimicrobial for veterinary use, and it does not have a monograph in an official compendium for the pharmaceutical form in tablets."( Eco-Friendly UV Spectrophotometric Method for Evaluation of Marbofloxacin in Tablets: Stability Study.
da Silva, TLA; Kogawa, AC; Lustosa, IA; Torres, IMS, 2022
)
2.41
"Marbofloxacin (MAR) is an antimicrobial belonging to the fluoroquinolone class and is marketed in the form of tablets. There is no microbiological monograph in official compendia to evaluate the potency of the final product. "( Fast and New Microbiological Method for Evaluating the Potency of Marbofloxacin-Based Tablets.
Da Silva Júnior, JR; Ferreira, RGL; Kogawa, AC; Torres, IMS, 2023
)
2.59
"Marbofloxacin (MAR) is a fluoroquinolone antibiotic used in food-producing animals in European Union, especially in pigs. "( PBPK Model To Predict Marbofloxacin Distribution in Edible Tissues and Intestinal Exposure in Pigs.
Henri, J; Laurentie, M; Le Van Suu, M; Manceau, J; Nouichi, A; Rolland, JG; Sanders, P; Viel, A, 2023
)
2.67
"Marbofloxacin is a broad-spectrum fluoroquinolone, and an extra-label use has been reported in horse, sheep and goat. "( Population pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of marbofloxacin against Coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactiae pathogens in goats.
Andrés-Larrea, MIS; Bhardwaj, P; de la Fe, C; Dova, SW; Fernández-Varón, E; Litterio, NJ; Lorenzutti, AM; Rodríguez, CMC; Rubio-Langre, S; Serrano-Rodríguez, JM; Sidhu, PK, 2023
)
2.58
"Marbofloxacin (MAR) is a veterinary antimicrobial, marketed in injectable solution, oral suspension, and tablets. "( Green Method for Evaluation of Marbofloxacin Tablets by HPLC and Evaluation of Interchangeability With UV and Turbidimetric Methods.
de Oliveira Neto, JR; de Oliveira, AS; de Oliveira, NRL; Kogawa, AC; Tavares, LL, 2023
)
2.64
"Marbofloxacin is a third-generation fluoroquinolone developed solely for veterinary medicine with a broad spectrum of antibacterial activity against some Gram-positive and most Gram-negative bacteria, including the bovine respiratory tract pathogen, Pasteurella multocida. "( Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model.
Cao, C; Liang, C; Lu, Y; Qiu, Z; Qu, Y; Sun, M; Zeng, Z, 2015
)
2.13
"Marbofloxacin is a fluoroquinolone veterinary antibiotic. "( Determination of marbofloxacin residues in beef and pork with an enzyme-linked immunosorbent assay.
Li, J; Li, QX; Sheng, W; Wei, K; Xia, X; Xu, T, 2009
)
2.14
"Marbofloxacin is a fluoroquinolone antibiotic expected to be effective in the treatment of infections involving gram-negative and some gram-positive bacteria in horses. "( Pharmacokinetics of marbofloxacin in horses.
Bernard, S; Bousquet-Melou, A; Schneider, M; Toutain, PL, 2002
)
2.08
"Marbofloxacin is a veterinary only, synthetic, broad spectrum fluoroquinolone antimicrobial agent. "( Identification and comparison of marbofloxacin metabolites from the plasma of ball pythons (Python regius) and blue and gold macaws (Ara ararauna).
Carpenter, JW; Coke, RL; Hunter, RP; Isaza, R; Koch, DE, 2007
)
2.06
"Marbofloxacin is a new fluoroquinolone developed exclusively for veterinary use. "( Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates.
Boisramé, B; Deleforge, J; Drugeon, H; Spreng, M; Thomas, V, 1995
)
2.03
"Marbofloxacin is a fluoroquinolone antimicrobial drug used in cattle for the treatment of respiratory infections. "( Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate.
Aliabadi, FS; Lees, P, 2002
)
1.99

Effects

Marbofloxacin has been shown to be effective and well tolerated in non-azotemic dogs with leishmaniasis. It has been recommended for the treatment of swine infections.

ExcerptReferenceRelevance
"Marbofloxacin has been shown to be effective and well tolerated in non-azotemic dogs with leishmaniasis."( Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease.
Aguilera-Tejero, E; Belinchon-Lorenzo, S; Garcia, P; Gomez-Nieto, LC; Lopez, I; Martinez-Moreno, JM; Morales, MC; Pineda, C; Rodriguez-Ortiz, ME, 2017
)
1.45
"Marbofloxacin has been recommended for the treatment of swine infections."( In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
Chen, Y; Fang, X; Huang, RJ; Huang, T; Liu, YH; Sun, J; Xiao, X; Yang, T; Zhou, YF, 2015
)
1.37
"Marbofloxacin has been licensed for use in various mammalian species, but not as yet for turkeys, although its kinetic properties distinguish it from other fluoroquinolones."( Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.
Fink-Gremmels, J; Haritova, AM; Lashev, LD; Parvanov, PR; Rusenova, NV, 2006
)
1.3

Treatment

Marbofloxacin treatment was given on days 16-44 pi to half of the Mhf-infected cats, and on days 49-77 pi tohalf of the CMhm- infected cats. Treatment was associated with a significant decrease in M.hf.

ExcerptReferenceRelevance
"Marbofloxacin treatment was given on days 16-44 pi to half of the Mhf-infected cats, and on days 49-77 pi to half of the CMhm-infected cats."( Acute phase response to Mycoplasma haemofelis and 'Candidatus Mycoplasma haemominutum' infection in FIV-infected and non-FIV-infected cats.
Barker, EN; Cerón, JJ; Eckersall, PD; Knowles, TG; Korman, RM; Tasker, S, 2012
)
1.1
"Marbofloxacin treatment was associated with a significant decrease in M."( Effect of chronic FIV infection, and efficacy of marbofloxacin treatment, on Mycoplasma haemofelis infection.
Caney, SM; Day, MJ; Dean, RS; Gruffydd-Jones, TJ; Helps, CR; Knowles, TG; Lait, PJ; Pinches, MD; Tasker, S, 2006
)
1.31
"Treatment with marbofloxacin (2.75 mg/kg PO daily for 14 days) was initiated in 6 randomly selected cats when PCV was <30% or fever was >102.5 degrees F (39.2 degrees C)."( Marbofloxacin for the treatment of experimentally induced Mycoplasma haemofelis infection in cats.
Cavanaugh, MT; Dowers, KL; Hawley, JR; Ishak, AM; Lappin, MR; Powell, CC; Radecki, SV,
)
1.91

Toxicity

ExcerptReferenceRelevance
" Fluoroquinolones are commonly used medications to treat severe avian bacterial infections; however, their adverse effects on birds remain understudied."( Reproductive toxicity of fluoroquinolones in birds.
Abdelsalam, EEE; Anisimov, N; Bandouchova, H; Havelkova, B; Heger, T; Hruba, H; Kanova, M; Kovacova, V; Nemcova, M; Piacek, V; Pikula, J; Sedlackova, J; Vitula, F, 2019
)
0.51
"Fluoroquinolones induce complex adverse effects on avian embryonic development, considerably reducing the performance of incubated eggs and hatching chicks."( Reproductive toxicity of fluoroquinolones in birds.
Abdelsalam, EEE; Anisimov, N; Bandouchova, H; Havelkova, B; Heger, T; Hruba, H; Kanova, M; Kovacova, V; Nemcova, M; Piacek, V; Pikula, J; Sedlackova, J; Vitula, F, 2019
)
0.51

Pharmacokinetics

The pharmacodynamic (PD) properties of the fluoroquinolone, marbofloxacin, were determined for the bovine respiratory tract pathogens Mannheima haemolytica and Pasteurella multocida. Because of favourable pharmacokinetic properties, marBofl Oxacin should be preferred for oral administration in Japanese quails and pheasants for treatment of infections caused by equally susceptible pathogens.

ExcerptReferenceRelevance
" Pharmacokinetic parameters were calculated by use of a noncompartment model."( [The effect of pregnancy and lactation in sows on the pharmacokinetics of the gyrase inhibitor marbofloxacin].
Petracca, K; Wanner, M, 1993
)
0.5
" Pharmacokinetic parameters were calculated by use of statistical moments."( Pharmacokinetics of the gyrase inhibitor marbofloxacin: influence of pregnancy and lactation in sows.
Graser, T; Petracca, K; Riond, JL; Wanner, M, 1993
)
0.55
" Time of maximum plasma concentration (Tmax) was similar for MAR and DIF; Tmax occurred earlier for ENR and later for CIP."( Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs.
Evans, EI; Frazier, DL; Thompson, L; Trettien, A, 2000
)
0.54
" Pharmacokinetic parameters were calculated by noncompartmental methods."( Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration.
Heinen, E, 2002
)
0.54
"The pharmacokinetic behavior of marbofloxacin was studied in goats after single-dose intravenous (i."( Pharmacokinetic behavior of marbofloxacin after intravenous and intramuscular administrations in adult goats.
De Vicente, ML; González, F; Rodríguez, C; San Andrés, MD; San Andrés, MI; Waxman, S, 2001
)
0.89
"To determine pharmacokinetic characteristics of marbofloxacin after a single IV and oral administration and tissue residues after serial daily oral administration in chickens."( Pharmacokinetic characteristics and tissue residues for marbofloxacin and its metabolite N-desmethyl-marbofloxacin in broiler chickens.
Anadón, A; Castellano, VJ; Díaz, MJ; Frejo, MT; Martínez, M; Martínez, MA; Martínez-Larrañaga, MR; Tafur, M, 2002
)
0.82
"Analysis of pharmacokinetic data obtained in this study reveals that a minimal therapeutic dose of 2 mg/kg, PO, every 24 hours should be appropriate for control of most infections in chickens."( Pharmacokinetic characteristics and tissue residues for marbofloxacin and its metabolite N-desmethyl-marbofloxacin in broiler chickens.
Anadón, A; Castellano, VJ; Díaz, MJ; Frejo, MT; Martínez, M; Martínez, MA; Martínez-Larrañaga, MR; Tafur, M, 2002
)
0.56
"The pharmacokinetic behavior of marbofloxacin was studied in seven healthy goats and in the same goats with induced fever after single-dose intravenous (i."( Influence of Escherichia coli endotoxin-induced fever on the pharmacokinetic behavior of marbofloxacin after intravenous administration in goats.
De Lucas, JJ; González, F; Rodríguez, C; San Andrés, MD; San Andrés, MI; Waxman, S, 2003
)
0.82
" In the post-distributive phase, marbofloxacin disappeared from aqueous humor with a half-life of 780 minutes."( Population pharmacokinetics of marbofloxacin in aqueous humor after intravenous administration in dogs.
Boisramé, B; Concordet, D; Regnier, A; Schneider, M; Toutain, PL, 2003
)
0.89
"The plasma and milk pharmacokinetics of marbofloxacin, a fluoroquinolone antibacterial compound, were evaluated in dairy cows, as well as its pharmacodynamic characteristics against mastitis-isolated pathogens."( Pharmacokinetics of marbofloxacin in lactating cows after repeated intramuscular administrations and pharmacodynamics against mastitis isolated strains.
Boisramé, B; Schneider, M; Vallé, M; Woehrlé, F, 2004
)
0.91
" Despite having different pharmacokinetic profiles, ibafloxacin and marbofloxacin produced similar results when used under field conditions at the recommended dosages."( Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles.
Horspool, LJ; Mawhinney, I; van den Bos, R; van Laar, P, 2004
)
0.81
"Population pharmacokinetic of marbofloxacin was investigated on 21 healthy and 16 diseased horses to assess interindividual variability of drug exposure."( Population pharmacokinetics of marbofloxacin in horses: preliminary analysis.
Bousquet-Mélou, A; Concordet, D; Doucet, MY; Peyrou, M; Schneider, M; Vrins, A, 2004
)
0.9
"Pharmacokinetic and pharmacodynamic properties of tolfenamic acid (TA) in calves were determined in serum and fluids of inflamed (carrageenan administered) and non-inflamed subcutaneously implanted tissue cages after intramuscular administration both alone and in combination with marbofloxacin (MB)."( Influence of marbofloxacin on the pharmacokinetics and pharmacodynamics of tolfenamic acid in calves.
Landoni, MF; Lees, P; Sidhu, PK, 2005
)
0.87
"Pharmacokinetic and pharmacodynamic properties in goats of the non-steroidal anti-inflammatory drug tolfenamic acid (TA), administered both alone and in combination with the fluoroquinolone marbofloxacin (MB), were established in a tissue cage model of acute inflammation."( Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats.
Landoni, MF; Lees, P; Sidhu, PK, 2006
)
0.76
" The ISF and plasma-unbound concentrations were similar during the steady-state period despite differences in lipophilicity and pharmacokinetic parameters of the drugs."( Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs.
Bidgood, TL; Papich, MG, 2005
)
0.55
" The pharmacodynamic parameters from time-kill kinetic studies provide a useful means of studying antimicrobial activity."( Comparison of faecal and optimal growth conditions on in vitro pharmacodynamic activity of marbofloxacin against Escherichia coli.
Gicquel-Bruneau, M; Laurentie, M; Pellet, T; Sanders, P, 2006
)
0.55
"The pharmacokinetic properties of marbofloxacin, a third generation fluoroquinolone, were investigated in six cats after single intravenous (IV) and repeat oral (PO) administration at a daily dose of 2 mg/kg."( Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats.
Albarellos, GA; Landoni, MF; Montoya, L, 2005
)
0.93
"The pharmacokinetic behavior of marbofloxacin was studied in goats after single-dose subcutaneous (SC) administration of 2mg/kg bodyweight."( Pharmacokinetic behavior and pharmacokinetic/pharmacodynamic integration of marbofloxacin after subcutaneous administration in goats.
De Lucas, JJ; Dova, SW; González, F; Rodríguez, C; San Andrés, MD; San Andrés, MI, 2007
)
0.85
" For example, the longer half-life of marbofloxacin in many animal species has been appreciated in veterinary practice."( Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.
Fink-Gremmels, J; Haritova, AM; Lashev, LD; Parvanov, PR; Rusenova, NV, 2006
)
0.85
" A repeated measures study has been designed to compare their pharmacokinetic parameters, to investigate their bioavailability and to estimate their absorbed fraction and first-pass effect by using plasma, urinary and metabolite data collected from five healthy mares."( Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction.
Bousquet-Melou, A; Doucet, MY; Laroute, V; Peyrou, M; Vrins, A, 2006
)
0.67
" administration of the drug, the elimination half-life (t(1/2 beta)) and mean residence time (MRT) were significantly longer in diseased calves (8."( Comparative pharmacokinetics of marbofloxacin in healthy and Mannheimia haemolytica infected calves.
El-Kattan, YA; Ismail, M, 2007
)
0.62
"3 mg/lb) and to compare pharmacokinetic variables after pharmacokinetic analysis by naïve averaged, naïve pooled, and nonlinear mixed-effects modeling."( Naïve averaged, naïve pooled, and population pharmacokinetics of orally administered marbofloxacin in juvenile harbor seals.
Huff, D; KuKanich, B; Papich, MG; Riviere, JE, 2007
)
0.56
" Maximum plasma concentration and area under the plasma-time concentration curve were approximately 3 microg/mL and 30 h x microg/mL, respectively."( Naïve averaged, naïve pooled, and population pharmacokinetics of orally administered marbofloxacin in juvenile harbor seals.
Huff, D; KuKanich, B; Papich, MG; Riviere, JE, 2007
)
0.56
"Values of pharmacokinetic variables were similar regardless of the analytic method used."( Naïve averaged, naïve pooled, and population pharmacokinetics of orally administered marbofloxacin in juvenile harbor seals.
Huff, D; KuKanich, B; Papich, MG; Riviere, JE, 2007
)
0.56
" Principal pharmacokinetic parameters were determined and two efficacy indices were computed by using pharmacokinetic parameters and selected mic90 values of marbofloxacin against pathogenic equine strains to predict the efficacy of the drug at this dose."( Pharmacokinetics of a single intravenous dose of marbofloxacin in adult donkeys.
De Lucas, JJ; González, F; Nieto, J; Rodríguez, C; San Andrés, MD; San Andrés, MI; Serres, C; Waxman, S, 2007
)
0.79
"The purpose of this study was to examine the allometric analyses of marbofloxacin, moxifloxacin, danofloxacin and difloxacin using pharmacokinetic data from the literature."( Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis.
Cox, SK, 2007
)
0.89
" Marbofloxacin concentrations were determined via reverse-phase high-performance liquid chromatography, and pharmacokinetic analysis of the data was performed with a mono-compartmental model."( Intraocular pharmacokinetics of intravenously administered marbofloxacin in rabbits with experimentally induced acute endophthalmitis.
Concordet, D; Regnier, A; Schneider, M; Toutain, PL, 2008
)
1.5
" Pharmacokinetic analysis of marbofloxacin was analyzed via noncompartmental methods."( Single- and multiple-dose pharmacokinetics of marbofloxacin after oral administration to rabbits.
Carpenter, JW; Hunter, RP; Koch, DE; Pollock, CG, 2009
)
0.9
" The absence of general adverse reactions in the turtles of the study, and the favourable pharmacokinetic properties (long half-life and high maximum plasma concentration) of MBX administered PO at the single-dose of 2 mg kg(-1) suggest the possibility of its safe and effective clinical use in loggerhead sea turtles."( Pharmacokinetics of marbofloxacin after a single oral dose to loggerhead sea turtles (Caretta caretta).
Cárceles, CM; Crescenzo, G; Di Bello, A; Lai, OR; Laricchiuta, P; Marín, P; Marzano, G, 2009
)
0.68
"The pharmacokinetic behavior of marbofloxacin was studied in healthy (n = 12) and Pasteurella multocida infected rabbits (n = 12) after single intravenous (i."( Influence of Pasteurella multocida infection on the pharmacokinetic behavior of marbofloxacin after intravenous and intramuscular administrations in rabbits.
Abo-el-Sooud, K; Goudah, A, 2010
)
0.87
"A mathematical pharmacodynamic model was developed to describe the bactericidal activity of marbofloxacin against Escherichia coli strains with reduced susceptibility levels (determined using MICs) under optimal and intestinal growth conditions."( Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains.
Andraud, M; Chauvin, C; Laurentie, M; Sanders, P, 2011
)
0.84
"The pharmacodynamic (PD) properties of the fluoroquinolone, marbofloxacin, were determined for the bovine respiratory tract pathogens Mannheima haemolytica and Pasteurella multocida."( Pharmacodynamics of marbofloxacin for calf pneumonia pathogens.
Cheng, Z; Fishwick, J; Illambas, J; Lees, P; Potter, T; Rycroft, A, 2013
)
0.96
" The concentration-time data were analysed by compartmental and non-compartmental pharmacokinetic methods."( Pharmacokinetics of marbofloxacin in rabbit after intravenous, intramuscular, and subcutaneous administration.
Alamo, LF; Cárceles, CM; Escudero, E; Fernández-Varón, E; Hernandis, V; Marín, P, 2013
)
0.71
"A population approach was used to evaluate the pharmacokinetic parameters of 3 fluoroquinolones administered to Japanese quail (Coturnix coturnix japonica)."( Comparative pharmacokinetics of enrofloxacin, danofloxacin, and marbofloxacin after intravenous and oral administration in Japanese quail (Coturnix coturnix japonica).
Dimitrova, D; Dinev, T; Haritova, A; Lashev, L; Moutafchieva, R, 2013
)
0.63
" The pharmacokinetic properties of marbofloxacin in serum, inflamed tissue-cage fluid (exudate), and noninflamed tissue-cage fluid (transudate) were studied by using a tissue-cage model."( Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue-cage model in yellow cattle.
Ding, H; Li, Z; Liang, C; Lv, Z; Shan, Q; Wang, J; Yang, F; Zeng, Z, 2014
)
0.93
" Pharmacokinetic parameters were calculated using noncompartmental methods."( Pharmacokinetics of marbofloxacin in pigs after intravenous and intramuscular administration of a single dose of 8 mg/kg: dose proportionality, influence of the age of the animals and urinary elimination.
Dron, F; Paulin, A; Schneider, M; Woehrlé, F, 2014
)
0.73
"The association between physiologically dependent pharmacokinetic parameters (CL(B), T1/2beta, Vd(ss)) of marbofloxacin and body weight was studied in eight animal species based on allometric equation Y = aWb, where 'Y' is the pharmacokinetic parameter, 'W' is body weight, 'a' is allometric coefficient (intercept) and 'b' is the exponent that describes relation between pharmacokinetic parameter and body weight."( Allometric scaling of marbofloxacin pharmacokinetics: a retrospective analysis.
Hossain, MA; Kim, JY; Kwak, DM; Lee, SJ; Park, SC; Suh, JW; Yohannes, S, 2014
)
0.93
" Mean residence time and mean elimination half-life for regimen 2 (9."( Comparison of pharmacokinetics of marbofloxacin after subcutaneous administration of various multiple-dose regimens to water buffalo calves (Bubalus bubalis).
Andrés, MD; Andrés, MI; Baroni, EE; De Lucas, JJ; Rubio, S, 2014
)
0.68
" Because of favourable pharmacokinetic properties, marbofloxacin should be preferred for oral administration in Japanese quails and pheasants for treatment of infections caused by equally susceptible pathogens."( Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants.
Dimitrova, DJ; Lashev, LD; Milanova, A; Moutafchieva, RG, 2015
)
0.94
" Whereas, the pharmacokinetic was conducted in rats by administering either MAR alone or combined with MG through oral and/or intravenous routes."( Evaluation of the pharmacokinetic-pharmacodynamic integration of marbofloxacin in combination with methyl gallate against Salmonella Typhimurium in rats.
Birhanu, BT; Lee, EB; Park, SC, 2020
)
0.8
"A meta-analysis conducted by combining five sets of previously published pharmacokinetic data, obtained in clinical and nonclinical settings."( Determination of the pharmacokinetic-pharmacodynamic cut-off values of marbofloxacin in horses to support the establishment of a clinical breakpoint for antimicrobial susceptibility testing.
Bousquet-Mélou, A; Broussou, DC; Damborg, P; El Garch, F; Ferran, AA; Lallemand, EA; Schneider, M; Toutain, PL; Triboulloy, C, 2021
)
0.85
" However, extrapolation of dosage regimens from cattle to horse and small ruminants could lead to incorrect dosing due to pharmacokinetic differences among species, increasing the risk of antimicrobial resistance or toxicity."( Population pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of marbofloxacin against Coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactiae pathogens in goats.
Andrés-Larrea, MIS; Bhardwaj, P; de la Fe, C; Dova, SW; Fernández-Varón, E; Litterio, NJ; Lorenzutti, AM; Rodríguez, CMC; Rubio-Langre, S; Serrano-Rodríguez, JM; Sidhu, PK, 2023
)
1.14

Compound-Compound Interactions

Study was carried out to investigate the effect of piperine and quercetin alone or in combination with marbofloxacin on CYP3A37 and MDR1 mRNA expression levels in liver and intestine of broiler chicken. New liquid-liquid extraction method combined with HPLC-MS/MS was developed.

ExcerptReferenceRelevance
"In a four-period cross-over study, the fluoroquinolone antibacterial drug marbofloxacin (MB) was administered to goats intramuscularly (IM) at a dose rate of 2 mg/kg, both alone and in combination with the non-steroidal anti-inflammatory drug tolfenamic acid (TA), also administered IM at a dose rate of 2 mg/kg."( Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in goats.
Aliabadi, FS; Landoni, MF; Lees, P; Sidhu, PK, 2010
)
0.85
"In a four-period, cross-over study, the fluoroquinolone antibacterial drug marbofloxacin (MB) was administered to calves, alone and in combination with the nonsteroidal anti-inflammatory drug tolfenamic acid (TA)."( Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in calves.
Aliabadi, MH; Landoni, MF; Lees, P; Sidhu, PK; Toutain, PL, 2011
)
0.85
" The efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum was assessed in vitro by incubating increasing concentrations of the drugs with a standard parasite inoculum."( Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.
Badino, P; Farca, AM; Ferroglio, E; Miniscalco, B; Monticelli, P; Odore, R; Trisciuoglio, A, 2012
)
0.9
" Therefore, a new liquid-liquid extraction method combined with HPLC-MS/MS for the detection of marbofloxacin, ciprofloxacin, enrofloxacin and difloxacin in chicken feces was developed."( Determination of fluoroquinolones in chicken feces - a new liquid-liquid extraction method combined with LC-MS/MS.
Hamscher, G; Janusch, F; Mohring, SA; Scherz, G, 2014
)
0.62
" Furthermore, MG alone or in combination with sub-MIC of MRB decreased the motility of Salmonella Typhimurium."( Inhibition of Salmonella Typhimurium adhesion, invasion, and intracellular survival via treatment with methyl gallate alone and in combination with marbofloxacin.
Birhanu, BT; Hossain, MA; Lee, SJ; Park, NH; Park, SC, 2018
)
0.68
" This study was carried out to investigate the effect of piperine and quercetin alone or in combination with marbofloxacin on CYP3A37 and MDR1 mRNA expression levels in liver and intestine of broiler chicken."( Effect of piperine and quercetin alone or in combination with marbofloxacin on CYP3A37 and MDR1 mRNA expression levels in broiler chickens.
Mathapati, BS; Modi, CM; Patel, HB; Patel, UD, 2019
)
0.97
" Whereas, the pharmacokinetic was conducted in rats by administering either MAR alone or combined with MG through oral and/or intravenous routes."( Evaluation of the pharmacokinetic-pharmacodynamic integration of marbofloxacin in combination with methyl gallate against Salmonella Typhimurium in rats.
Birhanu, BT; Lee, EB; Park, SC, 2020
)
0.8

Bioavailability

The oral bioavailability of marbofloxacin was close to 100% for the three doses. The highest bioavailability was observed for danofl Oxacin. Very low bioavailability with significant conversion to ciprofloxacins was observed.

ExcerptReferenceRelevance
" Bioavailability was about 80% in pregnant and lactating sows."( [The effect of pregnancy and lactation in sows on the pharmacokinetics of the gyrase inhibitor marbofloxacin].
Petracca, K; Wanner, M, 1993
)
0.5
" Bioavailability was about 80% in pregnant and lactating sows."( Pharmacokinetics of the gyrase inhibitor marbofloxacin: influence of pregnancy and lactation in sows.
Graser, T; Petracca, K; Riond, JL; Wanner, M, 1993
)
0.55
" The oral bioavailability of marbofloxacin was close to 100% for the three doses."( Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration.
Boisrame, B; Deleforge, J; Schneider, M; Thomas, V, 1996
)
0.91
"9 h) and had high bioavailability (F=100."( Pharmacokinetic behavior of marbofloxacin after intravenous and intramuscular administrations in adult goats.
De Vicente, ML; González, F; Rodríguez, C; San Andrés, MD; San Andrés, MI; Waxman, S, 2001
)
0.6
"2 min) and presented high bioavailability (F = 87."( Pharmacokinetics of marbofloxacin in mature horses after single intravenous and intramuscular administration.
Carretero, M; de Lucas, JJ; Forés, P; González, F; Nieto, J; Rodríguez, C; San Andrés, MD; San Andrés, MI; Waxman, S, 2002
)
0.64
" Oral bioavailability of marbofloxacin was 56."( Pharmacokinetic characteristics and tissue residues for marbofloxacin and its metabolite N-desmethyl-marbofloxacin in broiler chickens.
Anadón, A; Castellano, VJ; Díaz, MJ; Frejo, MT; Martínez, M; Martínez, MA; Martínez-Larrañaga, MR; Tafur, M, 2002
)
0.86
"316 microg/mL, and bioavailability was 90."( Pharmacokinetics of marbofloxacin in blue and gold macaws (Ara ararauna).
Carpenter, JW; Henry, H; Hunter, RP; Isaza, R; Koch, DE; Olsen, JH, 2006
)
0.66
" A repeated measures study has been designed to compare their pharmacokinetic parameters, to investigate their bioavailability and to estimate their absorbed fraction and first-pass effect by using plasma, urinary and metabolite data collected from five healthy mares."( Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction.
Bousquet-Melou, A; Doucet, MY; Laroute, V; Peyrou, M; Vrins, A, 2006
)
0.67
" Due to the poor oral bioavailability of many drugs in the horse, this method may be useful for screening drugs before development to determine if they warrant further study."( Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation.
Blikslager, AT; Davis, JL; Little, D; Papich, MG, 2006
)
0.33
"5 h, and an absolute bioavailability (F %) of 86."( Single-dose pharmacokinetics of marbofloxacin in Egyptian buffalo (Bubalus bubalis L.) steers.
Abd El-Aty, AM; Goudah, A; Regmi, NL; Shim, JH; Shimoda, M; Shin, HC,
)
0.41
"65 h and bioavailability 106%."( PK-PD integration and modeling of marbofloxacin in sheep.
Aliabadi, FS; Landoni, MF; Lees, P; Sidhu, PK, 2010
)
0.64
" The highest bioavailability was observed for danofloxacin followed by marbofloxacin, while very low bioavailability with significant conversion to ciprofloxacin was observed for enrofloxacin."( Comparative pharmacokinetics of enrofloxacin, danofloxacin, and marbofloxacin after intravenous and oral administration in Japanese quail (Coturnix coturnix japonica).
Dimitrova, D; Dinev, T; Haritova, A; Lashev, L; Moutafchieva, R, 2013
)
0.86
" The absolute bioavailability of marbofloxacin as well as the dose proportionality was evaluated in 27-week-old fattening pigs."( Pharmacokinetics of marbofloxacin in pigs after intravenous and intramuscular administration of a single dose of 8 mg/kg: dose proportionality, influence of the age of the animals and urinary elimination.
Dron, F; Paulin, A; Schneider, M; Woehrlé, F, 2014
)
1.01
" Higher bioavailability was observed for marbofloxacin (118%)."( Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants.
Dimitrova, DJ; Lashev, LD; Milanova, A; Moutafchieva, RG, 2015
)
0.96
" The Loo-Riegelman and staircase deconvolution function methods were found to provide more reliable estimates of absorption rate than the Spath-spline and B-spline constraining break points deconvolution methods."( Using deconvolution to understand the mechanism for variable plasma concentration-time profiles after intramuscular injection.
Grice, JE; Liu, X; Mahmood, AH; Medley, GA; Roberts, MS, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Naturally available phyto chemicals like piperine and quercetin as well as some floroquinolones are known to inhibit MDR1 and CYP3A37 activity and increases bioavailability of co-administered drugs."( Effect of piperine and quercetin alone or in combination with marbofloxacin on CYP3A37 and MDR1 mRNA expression levels in broiler chickens.
Mathapati, BS; Modi, CM; Patel, HB; Patel, UD, 2019
)
0.75

Dosage Studied

Marbofloxacin was safe and effective for the treatment of superficial and deep pyoderma in dogs at the dosage used in this study. Administration of marbofLoxacins at a dosage of 5 mg/kg, PO, every 24 hours is recommended for rabbits to control infections attributable to susceptible bacteria.

ExcerptRelevanceReference
" Each cat underwent a bacteriological examination before treatment (day 0) and received either marbofloxacin, at a dosage of 2 mg/kg once daily for five days, or amoxycillin-clavulanic acid (ACA) at a dosage of 12."( Comparative field evaluation of marbofloxacin tablets in the treatment of feline upper respiratory infections.
Dossin, O; Gruet, P; Thomas, E, 1998
)
0.8
" In conclusion, renal impairment has no biologically relevant influence on marbofloxacin disposition and there is no need for dosage adjustment of marbofloxacin in dogs with mild renal impairment."( Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog.
Costes, G; Delesalle, L; Dupouy, V; Laroute, V; Lefebvre, HP; Schneider, M; Toutain, PL, 1998
)
0.77
" This article proposes that dosage schedules should be developed to provide a basis for the rational use of antimicrobial drugs."( Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation.
AliAbadi, FS; Lees, P, 2000
)
0.31
" Marbofloxacin was safe and effective for the treatment of superficial and deep pyoderma in dogs at the dosage used in this study."( Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial.
Abbey, L; Baker, B; Coyne, M; Hannigan, M; Joffe, D; Paradis, M; Pukay, B; Trettien, A; Waisglass, S; Wellington, J, 2001
)
1.49
" In this investigation the pharmacokinetics (PK) of marbofloxacin were determined after intravenous and intramuscular dosing at a dosage of 2 mg/kg."( Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate.
Aliabadi, FS; Lees, P, 2002
)
0.8
" The 26% reduction in theophylline clearance is probably not clinically significant in healthy dogs, but for dogs with renal impairment, there might be a chance of theophylline accumulation when dosed concomitantly with marbofloxacin."( The effect of orally administered marbofloxacin on the pharmacokinetics of theophylline.
Dederichs, D; Hirt, RA; Teinfalt, M; van den Hoven, R, 2003
)
0.78
"Dogs with superficial or deep pyoderma (n = 228) presented to first opinion veterinarians (n = 20) were treated orally with either ibafloxacin, at a dosage of 15 mg/kg, or marbofloxacin, at a dosage of 2 mg/kg, once daily for 3-16 weeks."( Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles.
Horspool, LJ; Mawhinney, I; van den Bos, R; van Laar, P, 2004
)
0.77
" From the pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters after dosing with TA alone for serum TxB2 and exudate PGE2 expressing efficacy (Emax=69."( Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats.
Landoni, MF; Lees, P; Sidhu, PK, 2006
)
0.57
" Serum marbofloxacin disposition was best described by bicompartmental and mono-compartmental open models with first-order elimination after IV and oral dosing respectively."( Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats.
Albarellos, GA; Landoni, MF; Montoya, L, 2005
)
1.11
" Plasma concentrations attained with a dosage of 5 mg/kg every 24 hours would be expected to be efficacious for treatment of infections caused by susceptible bacteria (excluding Pseudomonas aeruginosa)."( Naïve averaged, naïve pooled, and population pharmacokinetics of orally administered marbofloxacin in juvenile harbor seals.
Huff, D; KuKanich, B; Papich, MG; Riviere, JE, 2007
)
0.56
"0 mg/kg body weight dosage to five healthy Egyptian buffalo steers."( Single-dose pharmacokinetics of marbofloxacin in Egyptian buffalo (Bubalus bubalis L.) steers.
Abd El-Aty, AM; Goudah, A; Regmi, NL; Shim, JH; Shimoda, M; Shin, HC,
)
0.41
"This phase II, randomized, open-label field trial was designed to evaluate and compare the safety and efficacy of four treatment durations (10, 20, 28 or 40 days) with marbofloxacin administered orally at the dosage of 2mg/kg once a day for canine visceral leishmaniosis."( Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study.
Fournel, S; Pérès, S; Rougier, S; Vouldoukis, I; Woehrlé, F, 2008
)
0.8
" These data were used to predict once daily dosage schedules of MB for subsequent clinical evaluation."( Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in goats.
Aliabadi, FS; Landoni, MF; Lees, P; Sidhu, PK, 2010
)
0.62
" Administration of marbofloxacin at a dosage of 5 mg/kg, PO, every 24 hours is recommended for rabbits to control infections attributable to susceptible bacteria."( Single- and multiple-dose pharmacokinetics of marbofloxacin after oral administration to rabbits.
Carpenter, JW; Hunter, RP; Koch, DE; Pollock, CG, 2009
)
0.94
" Using a rat lung infection model, we measured the influence of different marbofloxacin dosage regimens on selection of resistant bacteria after infection with a low (10(5) CFU) or a high (10(9) CFU) inoculum of Klebsiella pneumoniae."( Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.
Bousquet-Mélou, A; Ferran, AA; Kesteman, AS; Laurentie, M; Perrin-Guyomard, A; Sanders, P; Toutain, PL, 2009
)
0.87
" Appropriate dosing regimens could mitigate this adverse effect."( Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.
Bousquet-Mélou, A; Kesteman, AS; Laurentie, M; Perrin-Guyomard, A; Sanders, P; Toutain, PL, 2010
)
0.36
" Plasma concentrations of orally dosed marbofloxacin were too low to be quantified."( Absorption of enrofloxacin and marbofloxacin after oral and subcutaneous administration in diseased koalas (Phascolarctos cinereus).
Govendir, M; Griffith, JE; Higgins, DP; Krockenberger, MB; Li, KM, 2010
)
0.92
"3 and 4 hours (tmax) after dosing of 2 and 4 mg/kg BW, respectively."( Plasma and urine concentrations of marbofloxacin following single subcutaneous administration to cats.
Hoffmann, M; Kietzmann, M; Kramer, S; Niedorf, F; Pankow, R; Schneider, M; Vallé, M,
)
0.41
"New approaches in Pharmacokinetic/Pharmacodynamic (PK/PD) integration suggested that marbofloxacin, a fluoroquinolone already licensed for the treatment of bovine respiratory disease at a daily dosage of 2 mg/kg for 3-5 days, would be equally clinically effective at 10 mg/kg once (Forcyl(®)), whilst also reducing the risk of resistance."( Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease.
Galland, D; Giboin, H; Schneider, M; Vallé, M; Woehrlé, F, 2012
)
0.86
" The time course of free drug concentrations in canine serum was modelled, resulting from once daily standard oral dosing of 3 mg of PRA/kg and 2 mg of MAR/kg."( Comparative activity of pradofloxacin and marbofloxacin against coagulase-positive staphylococci in a pharmacokinetic-pharmacodynamic model based on canine pharmacokinetics.
Bagel-Trah, S; Hafner, D; Körber-Irrgang, B; Kresken, M; Wetzstein, HG, 2012
)
0.64
"88, respectively, after intravenous dosing and 160."( Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue-cage model in yellow cattle.
Ding, H; Li, Z; Liang, C; Lv, Z; Shan, Q; Wang, J; Yang, F; Zeng, Z, 2014
)
0.66
" Feces of chickens treated with an enrofloxacin dosage of 10mg/kg bodyweight revealed maximum enrofloxacin and ciprofloxacin concentrations of 61."( Determination of fluoroquinolones in chicken feces - a new liquid-liquid extraction method combined with LC-MS/MS.
Hamscher, G; Janusch, F; Mohring, SA; Scherz, G, 2014
)
0.4
" Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible."( In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
Chen, Y; Fang, X; Huang, RJ; Huang, T; Liu, YH; Sun, J; Xiao, X; Yang, T; Zhou, YF, 2015
)
1.56
"For all organisms and all drugs investigated in this study, it is suggested that broth MICs should be adjusted by an appropriate scaling factor when used to determine pharmacokinetic/pharmacodynamic breakpoints for dosage prediction."( Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.
Dorey, L; Lees, P, 2017
)
0.46
" Kids were randomly divided into two equal groups; the GM group received a single subcutaneous dose of GM at a dosage of 6 mg/kg and the MR group received MR intramuscularly at a dosage of 8 mg/kg as a single-dose."( Comparing clinical effects of marbofloxacin and gamithromycin in goat kids with pneumonia.
Batmaz, H; Kacar, Y; Mecitoglu, Z; Yilmaz, OE, 2018
)
0.77
" Antibiotic therapy was set based on the antibiogram, and marbofloxacin was chosen at a dosage of 10 mg/kg subcutaneously (SC) once per day (SID)."( Klebsiella sp.-related infectious spondylitis in a bearded dragon (Pogona vitticeps).
Bertocchi, M; Di Ianni, F; Gerosa, S; Moggia, E; Pelizzone, I; Vetere, A, 2021
)
0.87
" However, extrapolation of dosage regimens from cattle to horse and small ruminants could lead to incorrect dosing due to pharmacokinetic differences among species, increasing the risk of antimicrobial resistance or toxicity."( Population pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of marbofloxacin against Coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactiae pathogens in goats.
Andrés-Larrea, MIS; Bhardwaj, P; de la Fe, C; Dova, SW; Fernández-Varón, E; Litterio, NJ; Lorenzutti, AM; Rodríguez, CMC; Rubio-Langre, S; Serrano-Rodríguez, JM; Sidhu, PK, 2023
)
1.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency15.48890.006038.004119,952.5996AID1159521; AID1159523
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.71010.000229.305416,493.5996AID743079
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (68)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID372818Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'7 CFU/mL inside the mutant selection window for 0% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372810Bactericidal activity against marbofloxacin-resistant Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'5 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372815Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'7 CFU/mL inside the mutant selection window for 25% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372831T>MIC in Escherichia coli ATCC 25922 at time with in mutant selection window of 100%2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372813Bactericidal activity against marbofloxacin-resistant Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'9 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372817Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'5 CFU/mL inside the mutant selection window for 0% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID372833T>MIC in Escherichia coli ATCC 25922 at time with in mutant selection window of 0%2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372828Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'5 CFU/mL inside the mutant selection window for 0% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372825Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'5 CFU/mL inside the mutant selection window for 25% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372826Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'7 CFU/mL inside the mutant selection window for 25% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID584113Ratio of LD99 for Escherichia coli K-12 DM4100 to MIC for Escherichia coli K-12 DM41002010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.
AID372819Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'9CFU/mL inside the mutant selection window for 0% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID584112Bactericidal activity against Escherichia coli K-12 DM4100 after 2 hrs in presence of protein synthesis inhibitor chloramphenicol treated 10 mins before compound challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.
AID372821Bactericidal activity against marbofloxacin-resistant Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'5 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372834Effect on Escherichia coli ATCC 25922 assessed as time at which drug concentration above the mutant prevention concentration at time with in mutant selection window of 100%2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372835Effect on Escherichia coli ATCC 25922 assessed as time at which drug concentration above the mutant prevention concentration at time with in mutant selection window of 25%2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372811Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'7 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372809Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'5 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372807Antibacterial activity against Escherichia coli ATCC 25922 by microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372824Bactericidal activity against marbofloxacin-resistant Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'9 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372812Bactericidal activity against marbofloxacin-resistant Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'7 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372808Antibacterial activity against Escherichia coli ATCC 25922 assessed as mutant prevention concentration after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372822Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'7 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372827Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'9 CFU/mL inside the mutant selection window for 25% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372820Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'5 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372823Bactericidal activity against marbofloxacin-resistant Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'7 CFU/mL inside the mutant selection window for 100% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372836Effect on Escherichia coli ATCC 25922 assessed as time at which drug concentration above the mutant prevention concentration at time with in mutant selection window of 0%2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID584111Bacteriostatic activity against Escherichia coli K-12 DM41002010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.
AID372816Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'9CFU/mL inside the mutant selection window for 25% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372814Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as final bacterial count using inoculum size of 10'5 CFU/mL inside the mutant selection window for 25% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372829Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'7 CFU/mL inside the mutant selection window for 0% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372830Bactericidal activity against marbofloxacin-susceptible Escherichia coli ATCC 25922 assessed as area between the control curve and time kill curve using inoculum size of 10'9 CFU/mL inside the mutant selection window for 0% of time2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
AID372832T>MIC in Escherichia coli ATCC 25922 at time with in mutant selection window of 25%2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (230)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (6.09)18.2507
2000's72 (31.30)29.6817
2010's120 (52.17)24.3611
2020's24 (10.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.09 (24.57)
Research Supply Index5.62 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index130.39 (26.88)
Search Engine Supply Index3.63 (0.95)

This Compound (46.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials38 (15.97%)5.53%
Reviews3 (1.26%)6.00%
Case Studies18 (7.56%)4.05%
Observational0 (0.00%)0.25%
Other179 (75.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]